Clinical Pre-screening Protocol for Ovarian Cancer
← catalyst calendarNCT03877796 · readout ≤ 315 d
Sponsored by Allarity Therapeutics (industry) · ALLR — their whole pipeline →. With Amarex Clinical Research.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
60estimated
Sites
9
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-11 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-03-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ovarian Cancer
Intervention
- Device: Drug Response Predictor® (DRP)
Primary outcome
what the primary-completion date above is the date OFIdentification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug
measured up to 2 years
Permalink · ALLR's whole pipeline · Catalyst calendar · Every registered study · What changed